Narcolepsy: update on etiology, clinical features and treatment
DOI:
https://doi.org/10.23938/ASSN.0546Keywords:
Palabras clave. Cataplejía. Diagnóstico. Narcolepsia. Tratamiento. Oxibato sódico.Abstract
Narcolepsy is a disease that involves an alteration in the generation and organisation of sleep. The main symptoms are excessive daytime sleepiness and cataplexy, followed by hypnagogic hallucinations, sleep paralysis and disrupted nocturnal sleep. The prevalence of typical narcolepsy oscillates between 25-50: 100.000 in general. Recently there has been a peak incidence in patients born in the month of March. According to the new classification, the Multiple Sleep Latency Test (MSLT) is mandatory for diagnosing narcolepsy without cataplexy, and advisable for diagnosing narcolepsy with cataplexy. Until now, the attempt has been made to control each symptom by its own specific treatment. At present, new American and European treatment guidelines propose new drugs that act on all the symptoms. The application of new criteria of diagnosis and treatment has improved the diagnosis, giving better options of treatment.Downloads
References
1. WESTPHAL C. Eigentümliche mit Einschlafen verbundene Anafälle. Arch Psvchiatr Nervenkr 1877; 7: 631-35.
2. GÉLINEAU J. De la narcolepsie. Gazette des Hópitaux (Paris) 1880; 53: 626-628.
3. BEUSTERIEN KM, ROGERS AE, WALSLEBEN JA, EMSELLEM HA, REBLANDO JA, WANG L et al. Health-related quality of life effects of modafinil for treatment of narcolepsy. Sleep 1999; 22: 757-765.
https://doi.org/10.1093/sleep/22.6.757
4. DODEL R, PETER H, WALBERT T, SPOTTKE A, NOELKER C, BERGER K et al. The socioeconomic impact of narcolepsy. Sleep 2004; 27: 1123-1128.
https://doi.org/10.1093/sleep/27.6.1123
5. The International Classification of Sleeep Disorder. 2nd edition. Westchester, IL, USA: American Academy of Sleep Medicine 2005.
6. LONGSTRETH WT JR, KOEPSELL TD, TON TG, HENDRICKSON AF, VAN BELLE G. The epidemiology of narcolepsy. Sleep 2007; 30: 13-26.
https://doi.org/10.1093/sleep/30.1.13
7. BILLIARD M, DAUVILLIERS Y. Narcolepsy. En: Billiard M, ed. Sleep: Physiology, Investigations and Medicine. New York: Kluwer Academic/Plenum Publishers; 2003: 403-406.
https://doi.org/10.1007/978-1-4615-0217-3_31
8. OHAYON MM, PRIEST RG, ZULLEY J, SMIRNE S, PAIVA T. Prevalence of narcolepsy symptomatology and diagnosis in the European general populution. Neurology 2002; 58: 1826-1833.
https://doi.org/10.1212/WNL.58.12.1826
9. PABÓN RM, GARCÍA GURTUBAY I, RAMOS-ARGÜELLES F, GILA L, MORALES G, ALONSO MT. Narcolepsia. Una enfermedad infradiagnosticada. XLVI Reunión de la Sociedad Española de Neurofisiología Clínica. Rev Neurol 2008; 47: 547-555.
https://doi.org/10.33588/rn.4710.2008484
10. DAUVILLIERS Y, MONTPLAISIR J, MOLINARI N, CARLANDER B, ONDZE B, BESSET A et al. Age at onset of narcolepsy in two large populations of patients in France and Quebec. Neurology 2001, 57: 2029-2033.
https://doi.org/10.1212/WNL.57.11.2029
11. MORRISH E, KING MA, SMITH IE, SHNEERSON JM. Factors associated with a delay in the diagnosis of narcolepsy. Sleep Med 2004; 5: 37-41.
https://doi.org/10.1016/j.sleep.2003.06.002
12. DE LECEA L, KILDUFF TS, PEYRON C, GAO X, FOYE PE, DANIELSON PE et al. The hypocretins: Hypothalamus-specific peptides with neuroexcitatory activity. Oroc Natl Acad Sci USA 1998; 95: 322-327.
https://doi.org/10.1073/pnas.95.1.322
13. SAKURAY T, AMEMIYA A, ISHII M, MATSUZAKI I, CHEMELLI RM, TANAKA H et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G-protein. Coupled receptors that regulate feeding behavior. Cell 1998; 92: 573-585.
https://doi.org/10.1016/S0092-8674(00)80949-6
14. DEL CID-PELLITERO E, GARZÓN M. El sistema de neurotrasmisión hipocretinérgico/orexinergico en la regulación de los estados de vigilia y sueño. Rev Neurol 2007; 45: 482-490.
https://doi.org/10.33588/rn.4508.2006014
15. HAGAN JJ, LESLIE RA, PATEL S, EVANS ML, WATTAN TA, HOLMES S et al. Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc Natl Acad Sci USA 1999; 96: 10911-10916.
https://doi.org/10.1073/pnas.96.19.10911
16. DAUVILLIERS Y, CARLANDER B, MOLINARI N, DESAUTELS A, OKUN M, TAFTI M et al. Month of birth as a risk factor for narcolepsy. Sleep 2003; 26: 663-665.
https://doi.org/10.1093/sleep/26.6.663
17. LECENDREUX M, MARET S, BASSETTI C, MOUREN MC, TAFTI M. Clinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boy. J Sleep Res 2003; 12: 347-348.
https://doi.org/10.1046/j.1365-2869.2003.00380.x
18. HONDA Y, ASAKA A, TANAKA Y, JUJI T. Discrimination of narcolepsy by using genetic markers and HLA. Sleep Res 1983; 12: 254.
19. MATSUKI K, GRUMET FC, LIN X, GELB M, GUILLEMINAULT C, DEMENT WC et al. DQ (rather than DR) gene marks susceptibility to narcolepsy. Lancet 1992; 339: 1052.
https://doi.org/10.1016/0140-6736(92)90571-J
20. NISSHINO S, RIPLEY B, OVEREEM S, LAMMERS GJ, MIGNOT E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000; 355: 39-40.
https://doi.org/10.1016/S0140-6736(99)05582-8
21. PEYRON C, FARACO J, ROGERS W, RIPLEY B, OVEREEM S, CHARNAY Y et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000; 6: 991-997.
22. OVEREEM S, MIGNOT E, VAN DIJK JG, LAMMERS GJ. Narcolepsy: clinical features new pathophysiologic insights, and future perpectives. J Clin Neurophysiol 2001; 18: 78-105.
https://doi.org/10.1097/00004691-200103000-00002
23. THORPY M. Current concepts in the etiology, diagnosis and treatment of narcolepsy. Sleep Med 2001; 2: 5-17.
https://doi.org/10.1016/S1389-9457(00)00081-2
24. BILLIARD M, BASSETTI C, DAUVILLIERS Y, DOLENC-GROSELJ L, LAMMERS GJ, MAYER G et al. EFNS guidelines on management of narcolepsy. Eur J Neurol 2006; 13: 1035-1048.
https://doi.org/10.1111/j.1468-1331.2006.01473.x
25. LITTNER MR, KUSHIDA C, WISE M, DAVILA DG, MORGENTHALER T, LEE-CHIONG T et al. Practice parameters for clinical use of the multiple sleep latency test and the maintenance of wakefulness test. Standards of Practice Committee of the American Academy of Sleep Medicine. Sleep 2005; 28: 113-121.
https://doi.org/10.1093/sleep/28.1.113
26. KRYGER MH, WALLD R, MANFREDA J. Diagnoses received by narcolepsy patients in the year prior to diagnosis by a sleep specialist. Sleep 2002; 25: 36-41.
https://doi.org/10.1093/sleep/25.1.36
27. EGUÍA VM, CASCANTE JA. Síndrome de apnea-hipopnea del sueño. Concepto, diagnostico y tratamiento médico. An Sist Sanit Navar 2007; 30 (Suppl. 1): 53S-74S.
https://doi.org/10.4321/S1137-66272007000200005
28. MORGENTHALER TI, KAPUR VK, BROWN T, SWICK TJ, ALESSI C, AURORA RN et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Standards of Practice Committee of the American Academy of Sleep Medicine. Sleep 2007; 30: 1705-1711.
https://doi.org/10.1093/sleep/30.12.1705
29. POZA-ALDEA JJ. Tratamiento integral con oxibato sódico de los síntomas del síndrome narcolepsia-cataplejía. Rev Neurol 2009; 48: 27-31.
https://doi.org/10.33588/rn.4801.2008426
30. GEORGE CF, FELDMAN N, ZHENG Y, STEININGER TL, GRZESCHIK SM, LAI C et al. A 2-week, polysomnographic, safety study of sodium oxybate in obstructive sleep apnea syndrome. Sleep Breath (revista electrónica) 2010; 1522-1709 (consultado 25-01-2010). Disponible en:
https://doi.org/10.1007/s11325-009-0320-0
http://www.springerlink.com/content/x282v13138q5805q/
31. VIGNATELLI L, BILLIARD M, P CLARENBACH, GARCÍA-BORREGUERO D, KAYNAK D, LIESIENE V et al. EFNS guidelines on management of restless legs syndrome and periodic limb movement disorder in sleep. Eur J Neurol 2006; 13: 1049-1065.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
La revista Anales del Sistema Sanitario de Navarra es publicada por el Departamento de Salud del Gobierno de Navarra (España), quien conserva los derechos patrimoniales (copyright ) sobre el artículo publicado y favorece y permite la difusión del mismo bajo licencia Creative Commons Reconocimiento-CompartirIgual 4.0 Internacional (CC BY-SA 4.0). Esta licencia permite copiar, usar, difundir, transmitir y exponer públicamente el artículo, siempre que siempre que se cite la autoría y la publicación inicial en Anales del Sistema Sanitario de Navarra, y se distinga la existencia de esta licencia de uso.
